Gilead Sciences, Inc. (BIT:1GILD)

Market Cap	114.61B
Revenue (ttm)	27.77B
Net Income (ttm)	463.63M
Shares Out	n/a
EPS (ttm)	0.37
PE Ratio	247.19
Forward PE	n/a
Dividend	2.87 (3.10%)
Ex-Dividend Date	Mar 13, 2025

Volume	n/a
Average Volume	253
Open	92.49
Previous Close	93.65
Day's Range	92.49 - 92.49
52-Week Range	58.32 - 111.00
Beta	0.34
RSI	36.23
Earnings Date	Apr 24, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD